Comparative daily profiles with different preparations of lamotrigine: A pilot investigation

Epilepsy and Behavior

Volumn 13, Issue 1, 2008, Pages 127-130

  Nielsen, Kirsten Annette ^a   Dahl, Marit ^a   Tømmerup, Erling ^a   Wolf, Peter ^a,b  

^a DANISH EPILEPSY CENTRE   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Bioequivalence; Diurnal profiles; Generic substitution; Lamotrigine; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; ETHOSUXIMIDE; ETIRACETAM; GENERIC DRUG; LAMOTRIGINE; PHENOBARBITAL; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DENMARK; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; EPIDURAL HEMATOMA; EPILEPSY; EPILEPTIC STATE; FALLING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; RELAPSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADULT; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; TIME FACTORS; TRIAZINES;

EID: 46549088111     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.02.020     Document Type: Article

References (15)

1. Perucca E. Generic antiepileptic drugs: general overview [abstract]. Epilepsia 48 s7 (2007) 6
2. Dua T. Essential antiepileptic drugs and the treatment gap [abstract]. Epilepsia 48 s7 (2007) 6
3. Gidal B.E. Generic substitution [abstract]. Epilepsia 48 s7 (2007) 6
4. Wolf P. Political campaign in Denmark [abstract]. Epilepsia 48 s7 (2007) 6
5. Andermann F., Duh M.S., Gosselin A., and Paradis P.E. Compulsory generic switches of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48 (2007) 464-469
6. Krämer G., Steinhoff B.J., Feucht M., Pfäfflin M., and May T.W. Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss Branches of the ILAE. Epilepsia 48 (2007) 609-611
7. Bialer M. Generic products of antiepileptic drugs: is it an issue?. Epilepsia 48 (2007) 1825-1832
8. http://www.laegemiddelstyrelsen.dk/1024/visLSArtikel.asp?artikelID=6410.
9. http://www.medstat.dk/MedStatDataViewer.php.
10. Wolf P., May Th., Tiska G., and Schreiber G. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations. Drug Res 42 (1992) 284-288
11. Mayer Th., May T.W., Altenmüller D.-M., Sandmann M., and Wolf P. Clinical problems with generic antiepileptic drugs: comparison of sustained-release formulations of carbamazepine. Clin Drug Invest 18 (1999) 17-26
12. Søndergaard Khinchi M, Nielsen KA, Dahl M, Wolf P. Lamotrigine therapeutic thresholds. Seizure Eur J Epilepsy 2008, in press. doi:10.1016/j.seizure.2007.11.023.
13. Hirsch L.J., Weintraub D., Buchsbaum R., et al. Correlating LTG serum concentration with tolerability in patients with epilepsy. Neurology 63 (2004) 1022-1026
14. Nielsen K.A., Dahl M., Tømmerup M., á Rogvi Hansen B., and Erdal J Wolf P. Daily fluctuations of lamotrigine (LTG) plasma levels [abstract]. Epilepsia 48 s7 (2007) 42
15. Garnett W.R. Lamotrigine, interaction with other drugs. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic drugs. 5th ed. (2002), Lippincott, Williams, & Wilkins, Philadelphia 380-388